Med Surg Solutions successfully hosted the HDx – Advancements in Renal Care Workshop on November 7–8, 2025, at the Mövenpick Bosphorus Istanbul, Turkey. The two-day scientific meeting gathered distinguished nephrologists, clinical experts, and healthcare professionals to explore the evolving role of Expanded Hemodialysis (HDx) in advancing patient outcomes and redefining standards of renal care.
Day One: Advancing Science in Hemodialysis
Day One featured an exceptional lineup of international experts, including Prof. Sandip Mitra — Chairperson & Member of the European Dialysis Board, and National Chair for Research in Hospital Settings at the National Institute for Health and Care Research (NIHR) — alongside Dr. Ayman Karkar, Head of Medical Affairs for Renal Care, Vantive MEA; Dr. Kamel El Attar, Nephrologist & Head of Medical Affairs for Acute Therapies, Vantive ECEMEA; and Dr. Mohammed Ramadan, Nephrologist & Clinical Instructor, Prince Mutaib General Hospital, Jouf, KSA.
The sessions provided deep insights into the pathophysiology of uremic toxins, clinical innovations in HDx therapy, and the benefits of Medium Cut-Off (MCO) membranes. Through sessions that discussed innovation meeting the need for expanded hemodialysis, the safety and performance of MCO membranes, and comparative data between HDx and high-flux hemodialysis, participants examined how HDx enables superior clearance of larger middle molecules while maintaining albumin balance — delivering measurable improvements in dialysis efficacy and patient well-being.
Prof. Mitra presented findings from international HDx clinical trials, offering evidence of HDx’s growing role as a therapy of choice across global dialysis centers. Dr. Karkar expanded on key aspects such as acetate versus citrate hemodialysis and indications and contraindications for MCO therapy, while Dr. Ramadan highlighted clinical insights on heparin-free dialysis protocols, emphasizing HDx’s safety advantages for high-risk patients.
Day Two: Integrating Acute and Chronic Kidney Therapies
Day Two centered on the management of acute kidney injury (AKI) and the integration of HDx within critical care practices. The sessions were led by Dr. Kamel El Attar and Dr. Mohammed Ramadan, both of whom brought extensive experience in acute and continuous renal replacement therapies.
Dr. El Attar opened the day with an introduction to AKI and KDIGO guidelines, followed by Dr. Ramadan, who discussed recent insights into renal replacement therapy management and modality-related outcomes. A joint clinical case study session by both speakers provided hands-on perspectives on optimizing prescriptions and improving patient monitoring strategies.
The workshop concluded with a presentation by Dr. El Attar on Oxiris membrane technology, demonstrating its vital role in managing sepsis through cytokine and endotoxin removal — an innovation bridging critical care and renal replacement therapy.
Commitment to Empowering Health
Beyond its scientific impact, the workshop reaffirmed MSS’s ongoing commitment to advancing clinical knowledge and empowering healthcare professionals through education and evidence-based practice. By fostering dialogue, research exchange, and collaboration, MSS continues to drive meaningful progress in renal care — ensuring that empowering health and impacting lives remains central to its mission.
The HDx Advancements in Renal Care Workshop concluded with a networking session, where participants celebrated shared achievements and a collective vision for the future of renal therapy innovation.
